Kornimate/medical-research-clean huggingface dataset:
simplified assessment of left ventricular systolic function in septic shock patients

Conditions: Left Ventricular Systolic Dysfunction; Septic Shock

Summary: the assessment of left ventricular systolic function is based on the measurement of left ventricular ejection function (lvef) by the simpson biplane method. more recently, left ventricular global longitudinal strain (gls) has been developed to detect abnormalities of cardiac contractility in patients with preserved myocardial contractility. however, both tools are not always easy to collect in practice. this is why other ultrasound parameters have been proposed in the literature as a substitute for lvef and gls such as the doppler tissue imaging (dti)-derived mitral annular systolic peak s-wave velocity (s'), the mitral annular plane systolic excursion (mapse) and the longitudinal wall fractional shortening index (lwfs). the purpose of this project is to propose an algorithm using simple parameters (s' wave, lateral mapse, septal mapse, mean mapse and lwfs) to predict lvef and gls in order to diagnose patients with impaired systolic function and preserved ejection.


Eligibility criteria:
inclusion criteria: * patients hospitalized in the medical intensive care department of the amiens-picardie university hospital for the management of septic shock. * septic shock is defined by sepsis with a need for vasopressor amines to maintain a mean arterial pressure higher than or equal to 65 mmhg, and associated with hyperlactatemia (higher than 2 mmol/l). * a transthoracic echocardiography should be performed within 72 hours of the diagnosis of septic shock. exclusion criteria: * patient with cardiac arrhythmias, * patients with severe mitral or aortic valve disease, * patients with fused mitral doppler flow, * patients with insufficient echogenicity to allow a correct assessment of left ventricular systolic function.

Keywords: left ventricular systolic function global longitudinal strain septic shock
a research study looking at how semaglutide works in people with type 2 diabetes in switzerland, as part of local clinical practice (sure switzerland)

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to collect information on how semaglutide works in real world patients. participants will get semaglutide prescribed by the study doctor. the study will last for about 6 to 8 months. participants will be asked to complete some questionnaires about their health and diabetes treatment. participants will complete these questionnaires during their normally scheduled visits with the study doctor.


Eligibility criteria:
inclusion criteria: * signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol) * the decision to initiate treatment with commercially available semaglutide has been made by the patient/legally acceptable representative and the treating physician before and independently from the decision to include the patient in this study * male or female, age greater than or equal to 18 years at the time of signing informed consent * diagnosed with type 2 diabetes at least 12 weeks prior to inclusion * available and documented haemoglobin a1c (hba1c) value less than or equal to 12 weeks prior to initiation of semaglutide treatment exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * treatment with any investigational drug within 90 days prior to enrolment into the study * hypersensitivity to semaglutide or to any of the excipients
chlorhexidine vs povidone iodine vaginal prep in decreasing postoperative infection in total laparoscopic hysterectomy

Conditions: Preventative Laparoscopic Hysterectomy

Summary: this is a randomized control trial which will randomize patients who will be undergoing laparoscopic (conventional or robotic assisted) total hysterectomy to vaginal prep with 4% chlorhexidine gluconate vs 10% povidone iodine. there is paucity of information regarding the superiority of one over the other.

this is a randomized control trial. during surgery, preoperative vaginal prep is routinely done for hysterectomies. this can be completed with 10% povidone iodine or with 4% chlorhexidine preparation. this study will investigate whether the routine use of betadine vaginal prep in comparison to chlorhexidine prep is superior. patients will be informed of the study at the time of their preoperative visit in the gynecology clinic at time of surgical scheduling. the attached informed consent sheet will be given to the patient for their signature. the patients will be randomized to receive either 10% povidone iodine or with 4% chlorhexidine vaginal preparation solution. this is not anticipated to take extra time or resources in the operating room setting because the surgical vaginal preparation solutions are typically readily available in the operating room setting. the patients will be assigned an envelope when they are in clinic after they have signed the consent form and that will be the group they are randomized to. once the patients are randomized, it is anticipated that 50 patients will be enrolled in each study arm. following randomization patients will receive the vaginal preparation per the randomization assignment. the patient will be blinded to the study arm. the provider will not be blinded. follow-up will occur on postoperative day #1 by phone call, and at the 2-week and 6-week follow-up visits.

Eligibility criteria:
inclusion criteria: * patients who are scheduled for total laparoscopic hysterectomy exclusion criteria: * not able to consent in english or have allergy to the 10% povidone betadine or 4% chlorhexidine solution.

Keywords: 4% chlorhexidine 10% povidone iodine
a extension study to evaluate revusiran (aln-ttrsc) in patients with transthyretin (ttr) cardiac amyloidosis

Conditions: TTR-mediated Amyloidosis

Summary: the purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (aln-ttrsc). dosing has been discontinued; patients are being followed-up for safety.


Eligibility criteria:
inclusion criteria: * subjects who previously received and tolerated revusiran (aln-ttrsc) in the aln-ttrsc-002 study * adequate liver function * not pregnant or nursing exclusion criteria: * inadequate renal function * uncontrolled hypertension, ischemic heart disease or clinically significant cardiac arrhythmia * untreated hypo- or hyperthyroidism * prior major organ transplant

Keywords: cardiomyopathy heart failure fac amyloid transthyretin ttr rnai therapeutic
thread lift by use of retaining ligaments

Conditions: Face Lift; Suspension Technique; Minimal Invasive Surgery

Summary: in facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.the investigators propose the new method of the thread lifting the subdermal and subcutaneous layer with a fiberoptic needle by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments. for the intraoperative evaluation the tensiometer was applied and for the postoperative evaluation the face-q applied.

in facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.the investigators propose the new method of the thread lifting the subdermal and subcutaneous layer with a fiberoptic needle by use of the retaining ligaments. retrospective analysis was performed on 369 consecutive patients undergoing the suture suspension technique between january of 2012 and december of 2015, so called thread lift, using 3-0 v-loc 180 device for facial rejuvenation with (n=305) or without additional facial procedures (n=64). the follow-up period ranged from 22 months to 43 months postoperatively, with a mean of 34.3 months. there are asymmetry(n=2), scar revision(n=1), revision(n=4), dimpling(n=1), suboptimal outcomes(n=9), and stitch abscess(n=1). the thread lift by use of the retaining ligaments with v-lock barbed sutures can be recommended as an alternative technique in the facelift.

Eligibility criteria:
inclusion criteria: * primary case * secondary case exclusion criteria: * wide scar tissue on face * allergy to foreign body(thread) * no skin excess

Keywords: face lift thread lift retaining ligament v-loc sutures tensiometer face-q
effect of general anesthesia method on cardiac risk patients on ischemia modified markers

Conditions: Anesthesia

Summary: to examine the effects of the general anesthesia method chosen in non-cardiac surgical operations of patients with cardiac risk on the levels of cardiac markers

to examine the effects of the general anesthesia method chosen in non-cardiac surgical operations of patients with cardiac risk on the levels of cardiac markers like; serum levels of the creatine kinase, creatine kinase myocardial band, high sensitive troponin, heart-type fatty acid-binding protein, ischemia-modified albumin and albumin. and evaluate the effect of anesthesia method on haemodynamic.

Eligibility criteria:
inclusion criteria: * being 18 years or older * getting a score of 2 and above according to the lee cardiac index * having a non-cardiac surgical procedure that will take at least three hours * asa ii or iii exclusion criteria: * under 18 years old * those who refused to participate in the study * patients with chronic renal failure * patients with creatinine value ≥ 1.5 mg/dl * surgery that takes less than 3 hours * patients with liver failure * refusing to participate in the study * being allergic to the drugs used
osimertinib with stereotactic radiosurgery (srs) in brain metastases from egfr positive nsclc

Conditions: NSCLC; Non-small Cell Lung Cancer

Summary: investigating potential of controlling brain metastases in patients with egfr positive nsclc.

in patients with egfr positive nsclc with 1-10 brain metastases, we are investigating whether we can control the macro brain metastases with stereotactic radiosurgery (srs) and control the micro metastases with targeted agent osimertinib and avoid whole brain radiation that could potentially lead to significant cognitive decline.

Eligibility criteria:
inclusion criteria: * confirmed pathology of egfr mutation positive nsclc with new brain metastases. * ability to care for self and ability to walk 50% of waking hours (ecog performance status of 0-2) * 1-10 brain metastases with intra-cranial brain metastasis must measure 3cm or less in the greatest dimension. * hemoglobin ≥9 g/dl, white blood count absolute ≥3.0 x 10\^9/l, granulocyte count ≥1.5 x 10\^9/l, and platelet count ≥100 x 10\^9/l * serum bilirubin ≤ 1.5 x upper limit of normal (uln) * ast and/or alt ≤ 2 uln (≤ 5 x uln when clearly attributable to liver metastases) * serum creatinine ≤ 1.5 uln or calculated creatinine clearance \> 60ml/min * for women of childbearing potential-negative pregnancy test within one week prior to start of therapy. * for all sexually active male and female patients of reproductive potential, employ two methods of highly effective and acceptable forms of contraception throughout the study and for 120 days following the final dose of osimertinib. exclusion criteria: * patients with leptomeningeal metastases documented by mri or cerebrospinal fluid (csf). * significant intratumoral or peritumoral hemorrhage * brain metastases within 5 mm of the optic chiasm or optic nerve * brainstem metastases * gastrointestinal disorders with diarrhea as a major symptom * clinically significant or uncontrolled cardiac disease (nyha functional classification of 3 or 4) * pre-existing interstitial lung disease or pneumonitis * unable to undergo brain mri * hiv or hepatitis b or c * prior treatments must be resolved to an asymptomatic state at time of enrollment * medical conditions that could cause safety risks * currently receiving investigational cancer therapy. * mean qt interval corrected heart rate (qtc)≥470ms calculated from 3 ekgs * left ventricular ejection fraction (lvef) ≤ 50% * use of strong cyp3a inhibitors * use of strong cyp3a4 inducers * use of potent cyp2c8 inhibitors * hypersensitivity to osimertinib or any of its ingredients * corneal ulceration * pregnant or breast-feeding

Keywords: osimertinib
changes in ultrasonographic assessment of inflammation upon initiation of adalimumab combination therapy in chinese rheumatoid arthritis (ra) patients with inadequate response to methotrexate

Conditions: Rheumatoid Arthritis (RA)

Summary: prospective, post-marketing, multi-center, open-label study to explore if the initiation of adalimumab could influence grey-scale (gs) and power doppler (pd) ultrasonographic (us) score using 36-joint plus 4-tendon scoring system, and validate the applicability of different simplified us joint scoring systems.


Eligibility criteria:
inclusion criteria: * moderate to severe ra despite treatment with methotrexate (mtx). * eligible to use adalimumab according to the local label without any contraindication. * naïve to adalimumab, and participants with prior exposure to any other biologic disease-modifying antirheumatic drugs (dmards) should have experienced at least five half-lives of the biologics after treatment discontinuation. * participants for whom investigators decided to prescribe adalimumab as per local label and are initiating adalimumab at baseline. exclusion criteria: * other inflammatory condition which may affect the signs on joints ultrasound (eg, gouty arthritis, or other chronic rheumatic disease besides ra). * currently being treated with or has been treated with any investigational drug of chemical or biologic nature within a minimum of 30 days of the baseline visit. * participants with contraindication or are not appropriate to use adalimumab according to local label or investigators' judgment.

Keywords: power doppler (pd) ultrasonographic (us) rheumatoid arthritis (ra) disease activity scale (das) c-reactive protein (crp)
prevalence of pancreatic cysts during routine endoscopic ultra sound

Conditions: Pancreatic Cysts

Summary: the investigators are interested in performing a detailed examination of the pancreas via eus (endoscopic ultra sound)for patients referred for a non-pancreatic condition. the hypothesis is to make a statistical determination of how many pancreatic cysts the investigators discover incidentally.

the prevalence of incidental pancreatic cysts discovered during eus. (see data tables)

Eligibility criteria:
inclusion criteria: * the inclusion criteria included: patients \>18 years old with decision making capacity referred for eus for any other indication other than the evaluation of a known pancreatic cyst, solid mass, or suspected mass. exclusion criteria: * any known history or evidence of the following from any previous imaging study: pancreatic cyst, solid mass, suspected pancreatic mass, dilated main pancreatic duct * previous surgical resection of any portion of the upper gi tract such as billroth ii that would not permit complete eus exam of the pancreas * laboratory and/or clinical evidence of ongoing acute pancreatitis * previous pancreatic surgical resection * pregnancy * incarceration * high risk for sedation * coagulopathy and/or thrombocytopenia * the patients underwent a complete eus examination of the pancreas.

Keywords: pancreatic cysts incidentally found during eus
the study of early stage osteonecrosis of femoral head with human umbilical cord mesenchymal stem cells (19#isclife®-onfh)

Conditions: Osteonecrosis of Femoral Head

Summary: the purposes of the study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (huc-msc) in treating osteonecrosis of femoral head patients.

this is a randomized,double-blind, paralleled study. patients will be divided into two groups of experiment and control. all of them will receive core decompression of the femoral head, while experimental group patient will transplant huc-msc in addition. follow-up visit will occur on 1 month, 3 months, and 6 months after operation, and harris hip score was applied to evaluate the symptoms change.

Eligibility criteria:
inclusion criteria: * ficat classification is i, iia, or iib period * no obvious improvement or ingravescence by conservative treatment * patients or their statutory receive human umbilical cord mesenchymal stem cell of their own will, and signed informed consent form exclusion criteria: * ficat classification is third or fourth period * acute, chronic infection patients * combined with heart, lung, kidney disease, and cannot tolerate operation * ankylosing spondylitis patient * acetabular dysplasia patient * with tumor * clinical data deficient * hiv positive * pregnancy or breast feeding women * under other therapy that possibly influence msc security or efficacy

Keywords: osteonecrosis of femoral head umbilical cord mesenchymal stem cells
individualized approach vs. fixed approach

Conditions: Paroxysmal Atrial Fibrillation

Summary: the purpose of the current study is to assess differences regarding the acute efficacy, safety, procedural duration, radiation exposure and long-term success of the novel afa-pro in combination of an individualized shortened ablation protocol containing a reduced freezing time to the standard approach of a fixed ablation protocol in patients with symptomatic paf.


Eligibility criteria:
inclusion criteria: * age ≥18 years * the patient understands the nature of the study, treatment procedure and provides written informed consent * symptomatic paroxysmal atrial fibrillation as defined by the current guidelines * willing to comply with specified pre-, post- and follow-up testing, evaluations and requirements * expected to remain available (geographically stable) for at least 12 months after enrollment exclusion criteria: * atrial fibrillation secondary to a reversible cause or of non-cardiac origin * previous af ablation procedure * longstanding persistent af * documented left atrial thrombus on imaging (e.g., transesophageal echocardiogram, angiogram) * nyha functional class iv heart failure * unstable angina * left ventricular ejection fraction \< 30% * valvular disease requiring interventional treatment * cardiac surgery within 3 months prior to enrolment * left atrial size \> 55 mm as measured in the parasternal antero-posterior view * uncontrolled bleeding, diathesis, coagulopathy or pro-coagulant state * active systemic infection or sepsis * other co-morbid condition(s) that could limit the participant's ability to participate in the study or to comply with follow-up requirements, or impact the scientific integrity of the study.
regeneration of posterior cruciate ligament injury using hypoxic conditioned allogenic adipose mesenchymal stem cell and condition medium

Conditions: Adypose Mesenchimal Stem Cell; Ligament Rupture; Ligament Derived Conditined Medium

Summary: transplantation of allogenic adipose mesenchimal stem cell in hypoxic cultur condition with ligament- derived conitioned medium can enhance regeneration of posterior cruciate ligament rupture

this study is in vivo study to prove effect of transplantation of allogenic adipose mesenchimal stem cell in hypoxic cultur condition with ligament- derived conitioned medium in regeneration of posterior cruciate ligament rupture

Eligibility criteria:
inclusion criteria: * white male new zealand rabbit * weight 2500 - 3000 gram exclusion criteria: * have no disease

Keywords: adypose mesenchimal stem cell hypoxic culture conditioned ligament rupture ligament derived conditined medium
cervical laminectomy with or without lateral mass fixation in cervical spondylotic myelopathy

Conditions: Degenerative Cervical Myelopathy (DCM)

Summary: the cervical spine consists of seven cervical vertebrae joined by intervertebral disks and a complex network of ligaments. the cervical spine has a normal lordotic curve, and it is much more mobile than the thoracic or lumbar regions of the spine, which makes it more liable to both degenerative and traumatic disorders . degenerative cervical myelopathy (dcm) is the most common form of spinal cord dysfunction in adults. the incidence and prevalence of myelopathy due to degeneration of the spine are estimated at a minimum of 41 and 605 per million in north america and incidence of cervical spondylotic myelopathy-related hospitalizations has been estimated at 4.04/100,000 person-years. degenerative cervical myelopathy (dcm), earlier referred to as cervical spondylotic myelopathy, patients report neurological symptoms such as pain and numbness in limbs, poor coordination, imbalance, and bladder dysfunction. surgical management for patients with multilevel cervical myelopathy aims to decompress the spinal cord and restore the normal sagittal alignment using either an anterior approach or a posterior approach. multilevel anterior surgery is associated with complications such as increased surgical trauma and increased incidence of pseudarthrosis, graft dislodgement, and implant failure as the number of level increases.the posterior approach is optimal for multilevel stenosis using consecutive laminectomies however, although the effectiveness of cervical laminectomy was documented repeatedly, there were still concerns over postoperative kyphotic deformity, cervical instability, and late deterioration cervical laminectomy and fusion may be performed to avoid the potential complications of instability and kyphosis associated with cervical laminectomy alone. for the latter, dissection and removal of the posterior elements disrupts the normal biomechanics of the cervical spine, leading to post laminectomy deformity and instability our study aim to evaluate the multilevel cervical laminectomy alone, and multilevel cervical laminectomy with lateral mass fixation in patients with cervical spondylotic myelopathy regarding the clinical and radiological outcome for short term follow-up.


Eligibility criteria:
inclusion criteria: * signs and symptoms of spondylotic myelopathy at two or more level cervical canal stenosis after full filling clinical and radiological criteria exclusion criteria: * history of previous cervical intervention like (anterior cervical approach and laminoplasty ). * history of cervical trauma. * history of other neurological disorders such as( multiple sclerosis , stroke,aml,....etc). * patient with insuffient data. * uncontrolled dm, hypertension and thyroid disorders. * osterpenic or osteoporotic patients